Abstract

Background: The duration of viable Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) shedding in immunocompromised patients is still unknown. This case report describes the duration of viable SARS-CoV-2 in two immunocompromised patients with completely different clinical courses and further addresses the immunological aspects.

Case presentations: Oropharyngeal swaps were collected continuously during hospitalization for two immunocompromised patients infected with SARS-CoV-2 and sent for analysis to real time reverse transcription polymerase chain reaction (RT-PCR), viral culture assessed by plaque assay and full genome sequencing. Blood samples for flow cytometry and further immunological analysis were taken once during admission. One patient was without symptoms of Coronavirus disease 2019 (COVID-19) whereas the other had severe respiratory symptoms requiring a stay at an intensive care unit (ICU) and treatment with remdesivir and dexamethasone. Despite their difference in clinical courses, they both continuously shed SARS-CoV-2 with high viral loads in culture. Both patients had undetectable anti SARS-CoV-2 IgG levels about 2 weeks after the first positive real time RT-PCR test of SARS-CoV-2, marked expansions of virus reactive CD8+ T cells but cellular markers indicative of attenuated humoral immunity.

Conclusions: Our case illustrates the importance of distinguishing isolation guidelines for patients infected with SARS-CoV-2 according to their immunological status. Furthermore, it demonstrates the need for immune markers relating to viral shedding in immunocompromised patients.

Keywords: SARS-CoV-2, Immunocompromised host, Virus shedding, COVID-19
**Background**

The need to determine the duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) shedding in infected individuals and thereby estimate the period of infectiousness is of vital importance in containing the coronavirus disease 2019 (COVID-19) pandemic.

Measured by real time reverse transcription polymerase chain reaction (RT-PCR), infected patients shed virus for up to 83 days after symptom onset, but replicative virus were not detected by culture after 9 days of symptoms [1]. A study including 21 hospitalized COVID-19 patients showed that the median time from symptom onset to viral clearance in culture was 7 days [2]. These findings underline the isolation guidelines used by the World Health Organization (WHO) which state that SARS-CoV-2 infected persons can discontinue isolation 10 days after symptom onset plus at least 3 additional days without symptoms [3]. Regarding asymptomatic cases with SARS-CoV-2 infection, the duration of infectiousness is still uncertain. Asymptomatic patients appear to shed virus for longer periods than symptomatic patients, measured by real time RT-PCR, and this may reflect a weaker degree of immune activation [4]. Jiang et al. [5] reported shortened IgG sero-conversion times among asymptomatic compared to symptomatic patients, whereas Shirin et al. reported the opposite [6]. These deviating findings could be attributable to differences in study groups, methods of symptoms recollection, viral loads and sensitivity of immune assays or underlying immunity. Immune markers might be useful as determinants for prolonged SARS-CoV-2 shedding. A limited number of case reports indicate protracted viral shedding in immunocompromised patients observed in both real time RT-PCR and in viral culture [7–9] but these studies provided no detailed description of cellular immune status.

Here we report two cases of immunocompromised patients in which one patient had a severe course of COVID-19 whereas the other patient was asymptomatic.

**Case presentations**

**Patient 1**

A 66-year-old male, newly liver transplanted, was hospitalized on November 9, 2 days after symptom onset due to increased fatigue and tachypnea. An oropharyngeal swap on October 26 revealed that he was positive for SARS CoV-2 after close contact to known infected person on October 20. The patient had noted a diminished sense of taste and smell from November 1th, but was otherwise asymptomatic prior to admission. He received mycophenolate mofetil 500 mg twice daily, tacrolimus 4 mg x 2 and prednisolone 15 mg x 1. At admission, his peripheral oxygen saturation (SpO2), blood gas analysis and C-reactive protein (CRP) concentration were normal. During admission mycophenolate mofetil was paused and tacrolimus was reduced in dose. Prednisolone dosage was increased to 55 mg daily shortly after admission. On day 12 from symptom onset, he was transferred to the intensive care unit (ICU) for non-invasive ventilation. At the ICU he was treated with intravenous dexamethasone 6 mg daily and remdesivir 200 mg x 1 the first day and 100 mg x 1 the following 4 days. He gradually improved with a total ICU admission of 8 days and total hospitalization of 29 days.

**Viral culture**

The first viral culture on SARS-CoV-2 was performed the day after admission correlating to 3 days after symptom onset and 21 days after exposure. This showed a PCR Quantification Cycle-value (Cq value) at 21.7 and viral culture at 61,277 Plaque Forming Unit (PFU)/swab. The latter rose to 256,410 PFU/swab on symptom day 9, with the Cq value diminishing to 19.21. From symptom day 13 virus were no longer detected in cultures and his Cq value gradually increased and was 35.45 before hospital discharge corresponding to day 31 from symptom onset (Fig. 1A). Full genome sequencing showed a B.1.177 linage [see Additional file 1].

**Patient 2**

A 70-year-old male with multiple myeloma and previous autologous bone marrow transplantation. In July 2020, he had a pacemaker implanted. He received lenalidomide 25 mg daily. He was admitted on October 21 due to fever and elevated CRP concentration (130 mg/L). *Nocardia Farcinica* was detected in blood cultures and pus from abscesses on the left leg. Trans-esophageal echocardiography showed vegetation on the pacemaker electrode. The pacemaker was extracted and re-implanted after 6 weeks of antibiotic treatment for the disseminated *Nocardia* infection. Due to hospital policy, he was tested routinely every week for SARS-CoV-2 in real time RT-PCR during his 7-week long admission, and by week 4 the test was positive. He remained asymptomatic of the infection with SARS-CoV-2.

**Viral culture**

The first viral culture was done 9 days after the first positive real time RT-PCR test and plaque assay showed a viral load of 11,082 PFU/swab. Three days later, the viral load increased to 55,944 PFU/swab, despite no major clinical change, and with a steady Cq value of 22.33 and 22.57, respectively. Viral clearance in culture was observed after 12 days from the first positive real time RT-PCR test and after further 6 days, the real time RT-PCR test was negative (Fig. 1B). Whole genome
sequencing showed a B.1.1.298 lineage described as a Danish lineage containing the origin of the Y453F mutation associated with mink [see Additional file 1].

Immunological results from patient 1 and 2
Both COVID 19 patients had normal concentrations of circulating immunoglobulins, neutrophils and monocytes [see Additional file 2, Table 1]. Both patients had undetectable anti-SARS-CoV-2 IgG levels < 1 RU/mL (QuantiVac IgG) 16 (patient1) and 14 days (patient2), respectively, after the first positive real time RT-PCR test of SARS-CoV-2.

Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed and used for downstream applications: markedly reduced fractions (2% for both) of patients CD4+ T cells proliferated in response to allogeneic cells at day 6 although responding CD4+ T cells underwent a normal number of divisions [proliferation index, Additional file 2 Table 1] after allogeneic stimulation. Lymphocyte marker studies revealed expanded activated (HLA-DR+) CD3+ T cells and CD8+ CD38+ HLA-DR+ T cells in both patients. Frequencies of PD-1+ ICOS+ (% CD4+ CXCR5+) circulating T follicular helper cells (cT FH) among patients were comparable to those of controls and within normal range. Frequencies of CD19+ CD27+ CD38+ antibody secreting cells (ASC) were slightly elevated in patient 2 with myeloma [Additional file 2 Table 1].

Methods
For detailed description of laboratory methods, see Additional file 3.

Discussion and conclusions
Despite the clinical differences in these two immunocompromised patients, both continuously shed SARS-CoV-2 as measured by real time RT-PCR and had high viral loads in culture. To our knowledge, this is the first report describing the duration and amount of viable virus in an asymptomatic immunocompromised adult patient infected with SARS-CoV-2. Furthermore, not many studies have quantified viable virus. The significance of the amount of viable virus is still uncertain, but it must be assumed that higher viral load will mean greater infectivity.

Patient 1 shed viable virus until day 13 after symptom onset and 25 days after the first positive real time RT-PCR test. The real time RT-PCR was positive as far as 42 days after first positive test and remained positive during admission. This emphasizes that a positive real time RT-PCR not necessarily reflects replicative virus with implications for the estimation of SARS-CoV-2 transmissivity especially in
immunocompromised patients. The asymptomatic patient had viable virus 12 days after initial positive real time RT-PCR. At that time point, he was highly contagious based on plaque assay analysis showing a high viral load of 55,944 PFU/swab. According to WHO, asymptomatic patients can discontinue isolation after 10 days of isolation from the first positive test [3]. This case shows that the immunocompromised patient, though asymptomatic, can potentially shed viable SARS-CoV-2 after 10 days and therefore this patient deviates from the guidelines.

Whole genome sequencing showed two different virus lineages and whether this can explain the different clinical courses of COVID-19 is unknown.

As IgG seroconversion times in asymptomatic/mildly symptomatic COVID-19 patients diverge [5, 6], cellular immune markers may represent underlying determinants for seroconversion and viral shedding. Both patients displayed markedly reduced fractions of allo-responsive CD4+ T cells. Allo-responsive T cells are dependent upon cognate TCR-MHC-peptide interactions as is the generation of cTFH [10]. Patient 1 received a T cell repressive regimen while patient 2 was lymphopenic and received lenalidomid which suppresses CD4+ T cell proliferation in-vitro [11]. Patient 2 also suffered from a disseminated Nocardia infection, indicating compromised CD4+ T cell immunity. Hence, both patients reduced allo-reactive CD4+ T cell fractions were consistent with their impaired cTFH formation versus that of an immunocompetent COVID-19 patient (day 20: 7.14%) [12]. CT_{FH} are strong indicators for the generation of antibodies to protein antigens [10]. Expansion of viral sensitive CD8+ CD38+ HLA-DR+ T cells [12] was observed in both patients, consistent with their preserved fractions of allo-reactive CD8+ T cells [Additional file 2 Table 1]. Frequencies of ASC were slightly elevated in patient 2 with myeloma but still lower than the ASC frequencies reported in symptomaticCOVID-19, also during convalescence [12].

However, the surface markers CD27+, CD19+, and CD38+ are phenotypic characteristics associated with myeloma [13, 14], thereby questioning the immunological relevance of patient 2’s increased ASC frequencies. Compromised humoral immunity also characterizes myeloma patients. The strength of this case report is the inclusion of analyzes and description of cellular immune markers in both the asymptomatic and the symptomatic immunocompromised patient infected with SARS-CoV-2. Furthermore, the quantification of viable virus with plaque assay gives a more accurate picture of the duration of infectiveness. As a limitation, whole genome sequencing was only performed once during admission for both patients, and therefore potential mutations during hospitalization were not characterized.

In conclusion, both immunocompromised patients displayed marked expansions of virus reactive CD8+ T cells but cellular markers indicative of attenuated humoral immunity. Both patients shed high amounts of viable virus, despite completely different clinical courses and our cases indicate the importance of individual considerations relating to isolation for immunocompromised patients.

Abbreviations
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; RT-PCR: Reverse transcription polymerase chain reaction; COVID-19: Coronavirus disease 2019; ICU: Intensive care unit; Cq value: PCR quantification cycle-value; PFU: Plaque forming unit; PBMC: Peripheral blood mononuclear cells; cTFH, T follicular helper cells; ASC: Antibody secreting cells

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-021-06429-5.

Acknowledgements
First of all, we would like to thank the patients for their participation in this study. We thank Christian Nielsen and Anna Christine Nilsson for technical support. We thank Line Lundegård Bang and Ditte Sandfeld Tromby for excellent laboratory support and Thøger Gorm Jensen for fruitful counselling and advices.

Authors’ contributions
Conceptualization: LM, IJ, Methodology: RP, TA, KA, MS, Writing – original draft: MN, LM, KA. Funding acquisition: TA. All authors read and approved the final manuscript.

Funding
This work was supported by a Novo Nordisk grant, number [NNF20SA0062931]. The funder had no role in any part of this study.

Availability of data and materials
The dataset generated and analyzed for this cohort study is not publicly available due to the Danish Data Protection Law in accordance with approval by the Danish Data Protection Agency (unr. 20/16202).

Declarations
Ethics approval, consent to participate
This study was approved by the Regional Committees on Health Research Ethics for Southern Denmark ID 5-20200947C. Both patients gave informed written consent to participate in the study.

Consent for publication
Both patients gave written informed consent for the publication of these results.

Competing interests
On behalf of all authors, the corresponding author states that there are no competing interests.

Author details
1Department of Infectious Diseases, Odense University Hospital, J.B Winsløws Vey 4, 5000 Odense C, Denmark. 2Research Unit for Infectious Diseases, University of Southern Denmark, Odense, Denmark. 3Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. 4Research Unit for Clinical Microbiology, University of Southern Denmark, Odense, Denmark. 5Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
References

1. M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J. Schafer, and A. Ho, "SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis," (in eng), Lancet Microbe, vol. 2, no. 1, pp. e13-e22, Jan 2021, doi: https://doi.org/10.1016/s2666-5247(20)30172-5.

2. M. C. Kim et al., "Duration of Culturable SARS-CoV-2 in hospitalized patients with Covid-19," (in eng), N Engl J Med, Jan 27 2021, doi: https://doi.org/10.1056/NEJMc207040.

3. World Health. Criteria for releasing COVID-19 patients from isolation: scientific brief, 17 June 2020, vol. 2020. Geneva: World Health Organization; 2020. issue CC BY-NC-SA 3.0 IGO. [Online]. Available: https://apps.who.int/iris/handle/10665/332451. Accessed 31 May 2021

4. Q. X. Long, X.J. Tang, Q.L. Shi, Q. Li, H.J. Deng, J. Yuan, J.L. Hu, W. Xu, Y. Zhang, F.J. Lu, K. Su, F. Zhang, J. Gong, B. Wu, X.M. Liu, J.J. Li, J.F. Qiu, J. Chen, J.L. Huang, "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections," (in eng), Nat Med, vol. 26, no. 8, pp. 1200–1204, Aug 2020, doi: https://doi.org/10.1038/s41591-020-0965-6.

5. C. Jiang, Y. Wang, M. Hu, L. Wen, C. Wen, Y. Wang, W. Zhu, S. Tai, Z. Jiang, K. Xiao, N. R. Faria, E. de Clercq, J. Xu, G. Li, "Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)," (in eng), Clin Transl Immunol, vol. 9, no. 9, p. e1182, 2020, doi: https://doi.org/10.1002/cti2.1182.

6. T. Shirin, T. R. Bhuiyan, R. C. Charles, S. Amin, I. Bhuiyan, Z. Kawsar, A. Rahat, A. N. Alam, S. Sultana, M. A. Aleem, M. H. Khan, S. R. Khan, R. C. LaRocque, S. B. Calderwood, E. T. Ryan, D. M. Slater, S. Banu, J. Clemens, J. B. Harris, M. S. Flora, F. Qadi, "Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh," (in eng), Int J Infect Dis, vol. 101, pp. 220–225, Dec 2020, doi: https://doi.org/10.1016/j.ijid.2020.09.1484.

7. T. Aydillo et al., "Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer," (in eng), N Engl J Med, vol. 383, no. 26, pp. 2586–2588, Dec 24 2020, doi: https://doi.org/10.1056/NEJMc2031670.

8. J. H. Baang et al., "Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient," (in eng), J Infect Dis, vol. 223, no. 1, pp. 23–27, Jan 4 2021, doi: https://doi.org/10.1093/infdis/jiaa666.

9. V. A. Avanzato et al., "Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer," (in eng), Cell, vol. 183, no. 7, pp. 1901–1912.e9, Dec 23 2020, doi: https://doi.org/10.1016/j.cell.2020.10.049.

10. J. He et al., "Circulating precursor CCR7(lo)PD-1(hi) CXCR5 + CD4+ T cells indicate Thf cell activity and promote antibody responses upon antigen reexposure," (in eng), Immunity, vol. 39, no. 4, pp. 770–781, Oct 17 2013, doi: https://doi.org/10.1016/j.immuni.2013.09.007.

11. A. Busch, D. Zeh, V. Janzen, L.O. Mügge, D. Wolf, L. Fingerhut, C. Hahn-Ast, O. Mauer, P. Brossart, M. von Lilienfeld-Toal, "Treatment with lenalidomide induces immunoaotivating and counter-regulatory immunosuppressive changes in myeloma patients," (in eng), Clin Exp Immunol, vol. 177, no. 2, pp. 439–453, Aug 2014, doi: https://doi.org/10.1111/cei.12343.

12. I. Thevarajan, T. H. O. Nguyen, M. Koutsakos, J. Druce, L. Caly, C. E. van de Sandt, X. Jia, S. Nicholson, M. Catton, B. Cowie, S. Y. C. Tong, S. R. Lewin, K. Kedzierska, "Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19," (in eng), Nat Med, vol. 26, no. 4, pp. 453–455, Apr 2020, doi: https://doi.org/10.1038/s41591-020-0819-2.

13. L. Hansmann, L. Blum, C. H. Ju, M. Liedtke, W. H. Robinson, and M. M. Davis, "Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma," (in eng), Cancer Immunol Res, vol. 3, no. 6, pp. 650–660, Jun 2015, doi: https://doi.org/10.1158/2326-6066.CIR-14-0236-t.

14. T. Rasmussen, L. Jensen, and H. E. Johnsen, "The clonal hierarchy in multiple myeloma," (in eng), Acta Oncol, vol. 39, no. 7, pp. 765–770, 2000, doi: https://doi.org/10.1080/028418600750063479.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.